# PharmaCyte Biotech, Inc.: Form 10-Q/A for the period ended Oct 31, 2015

- Company: [PharmaCyte Biotech, Inc.](/companies/pmcb.md) (CIK 1157075)
- Form: 10-Q/A
- Filed: 2016-01-19
- Accepted by EDGAR: Jan 19, 2016, 06:14 ET
- Period: 2015-10-31
- Accession: 0001019687-16-004860
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1157075/000101968716004860/pharmacyte_10qa1-103115.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1157075/000101968716004860/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-10-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-08-01 to 2015-10-31 | $0 | us-gaap:Revenues |
| Revenue | 6 months, 2015-05-01 to 2015-10-31 | $0 | us-gaap:Revenues |
| Cost of revenue | 3 months, 2015-08-01 to 2015-10-31 | $0 | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2015-05-01 to 2015-10-31 | $0 | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2015-08-01 to 2015-10-31 | $0 | us-gaap:GrossProfit |
| Gross profit | 6 months, 2015-05-01 to 2015-10-31 | $0 | us-gaap:GrossProfit |
| Research and development | 3 months, 2015-08-01 to 2015-10-31 | $439.7k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2015-05-01 to 2015-10-31 | $595.4k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2015-08-01 to 2015-10-31 | −$1.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2015-05-01 to 2015-10-31 | −$3.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2015-08-01 to 2015-10-31 | $194 | us-gaap:InterestExpense |
| Interest expense | 6 months, 2015-05-01 to 2015-10-31 | $826 | us-gaap:InterestExpense |
| Net income | 3 months, 2015-08-01 to 2015-10-31 | −$1.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2015-05-01 to 2015-10-31 | −$3.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-08-01 to 2015-10-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2015-05-01 to 2015-10-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2015-05-01 to 2015-10-31 | −$2.1m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Cash and equivalents | at 2015-10-31 | $2.3m | us-gaap:Cash |
| Current assets | at 2015-10-31 | $2.8m | us-gaap:AssetsCurrent |
| Total assets | at 2015-10-31 | $8.0m | us-gaap:Assets |
| Current liabilities | at 2015-10-31 | $1.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-10-31 | $1.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2015-10-31 | $6.9m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 20,828 characters.

### Summary of Impact of Restatement on Financial Condition and Results of Operations

The Company restated its condensed consolidated financial statements as of and for the period ended October 31, 2015 to reflect adjustments made due to the correction of the treatment of the issuance of certain shares of common stock and certain warrants and certain other matters, as further described below, resulting in a material understatement to assets, a material overstatement to liabilities and a material understatement to stockholders’ equity. The nature and impact of these adjustments are more particularly described below and in Note 1A to the Restated Financial Statements.

The adjustments described above relate to the Company’s issuance of certain cashless warrants in connection with its entry into the Consultant Agreement during the year ended April 30, 2015 (for more information, see the Amended Form 10-K). The Company accounted for the cashless warrants as a derivative liability in the Original Form 10-K. However, upon further analysis, the Company determined that the cashless warrants should have been accounted for as equity in accordance with U.S. GAAP in the Original Form 10-K. Additionally, the Company determined that the Consultant Agreement, issuance of shares of common stock to the consultant pursuant to the Consultant Agreement and the issuance of certain cash warrants and the cashless warrants to the consultant should have been recorded as a prepaid asset and amortized over the term of the Consultant Agreement in accordance with U.S. GAAP in the Original Form 10-K. As a result of the Company’s determination that the cashless warrants should be accounted for as equity, and that the Consultant Agreement, stock issuance, cash warrants and cashless warrants should be accounted for as a prepaid asset, the Company increased general and administrative expenses by the net amount of $506,573 and $1,013,146 on its condensed consolidated statements of operations for the three and six months ended October 31, 2015, respectively, and increased prepaid expenses and other assets by the amount of $335,878, net of amortization, on its condensed consolidated balance sheet as of October 31, 2015, as set forth in the Restated Financial Statements. As a result of these adjustments, and the adjustment to our consolidated financial statements for the year ended April 30, 2015 as set forth in the Amended Form 10-K, the Company recorded an increase to its accumulated deficit in the amount of $578,382 and an increase to total stockholders’ equity in the amount of $335,878.

As set forth in the Restated Financial Statements, the effect of the timing of the recognition of the cashless warrant expense resulted in a decrease of $29,746 and $492,049 to total other income, an increase to general and administrative expenses of $506,573 and $1,013,146 (amortization of prepaid expenses) and an increase to reported net loss in the amount of $536,319 and $1,505,195 for the three months and six months ended October 31, 2015, respectively.

This summary does not purport to be a complete discussion of the impact of the restatement described above and additional effects of the restatement are presented below in this Management's Discussion and Analysis of Financial Condition and Results of Operations and in the Restated Financial Statements contained in this Amended Filing, including, but not limited to, Note 1A to the Restated Financial Statements.

### Forward-Looking Statements

This Amended Filing (“Report”) includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). All statements other than statements of historical fact are “forward-looking statements” for purposes of this Report, including any projections of earnings, revenue or other financial items, any statements regarding the plans and objectives of management for future operations, any statements concerning proposed new products or services, any statements regarding future economic conditions or performance, any statements regarding expected benefits from any transactions and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “estimates,” “potential” or “continue,” or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained in this Report are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. Thus, investors should refer to and carefully review information in future documents we file with the Commission. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risk and uncertainties, including, but not limited to, the risk factors set forth in “Part I, Item 1A – Risk Factors” of our Annual Report on Form 10-K filed with the Commission on July 29, 2015 and the Amended Form 10-K and for the reasons described elsewhere in this Report. All forward looking statements and reasons why results may differ included in this Report are made as of the date of this Report, and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this Report, the “Company,” “PharmaCyte Biotech,” “we,” “us” and “our” refer to PharmaCyte Biotech, Inc., a Nevada corporation, and, where appropriate, its subsidiaries.

Item 2 of this Report should be read in conjunction with the unaudited condensed consolidated financial statements and related notes included under Part I, Item 1, of this Report. "Financial Statements" referenced in this Report refer to the unaudited condensed consolidated financial statements and related notes included in Part I, Item 1, and to the "Financial Statements and Supplementary Data" of our Annual Report on Form 10-K for the year ended April 30, 2015.

### Overview

We are a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon our use of a licensed proprietary cellulose-based live cell encapsulation technology we refer to as Cell-in-a-Box®. We are working to advance clinical research and development of new cellular-based therapies in the oncology and diabetes arenas. We are now actively engaged with Austrianova Singapore Pte Ltd (“Austrianova”), Translational Drug Development, LLC (“TD2”), Clinical Network Services (CNS) Pty. Ltd. (“CNS”), Imaging Endpoints, LLC and other companies, physicians and scientists in preparing for clinical trials for our treatment of pancreatic cancer and its symptoms using encapsulated live cells similar to those used in previous Phase 1/2 and Phase 2 clinical trials in pancreatic cancer that employed the same technology. We are also involved in preclinical studies to develop a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes.

### Performance Indicators

Non-financial performance indicators used by management to manage and assess how the business is progressing will include, but are not limited to, the ability to: (i) acquire appropriate funding for all aspects of our operations; (ii) acquire and complete necessary contracts; (iii) complete activities for producing cells and having them encapsulated for the planned preclinical studies and clinical trials; (iv) have regulatory work completed to enable studies and trials to be submitted to regulatory agencies; (v) initiate all purity and toxicology cellular assessments; and (vi) ensure completion of cGMP produced encapsulated cells to use in our clinical trials.

There are numerous factors required to be completed successfully in order to ensure our final product candidates are ready for use in our clinical trials. Therefore, the effects of material transactions with related parties and certain other parties to the extent necessary for such an undertaking may have substantial effects on both the timeliness and success of our current and prospective financial position and operating results. Nonetheless, we are actively working to ensure strong ties and interactions to minimize the inherent risks regarding success. From our assessments to date, we do not believe there are factors which will cause materially different amounts to be reported than those presented in this Report and aim to assess this regularly to provide the most accurate information to our shareholders.

### Results of Operations (As Restated)

### Period ended October 31, 2015 compared to period ended October 31, 2014

### Revenue

We had no revenues in the periods ended October 31, 2015 and 2014.

### Operating Expenses and Loss from Operations (As Restated)

As a result of the restatement of our condensed consolidated financial statements as of and for the period ended October 31, 2015 relating to the change in the accounting treatment of cashless warrants, cash warrants and the common stock issuance under the Consultant Agreement, consolidated general and administrative expenses (consulting expense) increased by $506,573 and $1,013,146 for the three and six months ended October 31, 2015, respectively, which was attributable to the amortization of prepaid expense. Accordingly, consolidated general and administrative expenses increased from $222,039 to $728,612 for the three months ended October 31, 2015 and increased from $483,454 to $1,496,600 for the six months ended October 31, 2015.

The following tables summarize our Operating Expenses and Loss from Operations for the three and six months ended October 31, 2015 and 2014:

| Three Months Ended October 31, 2015 (Restated) | 2014 | Six Months Ended October 31, 2015 (Restated) | 2014 |
| ---: | ---: | ---: | ---: |
| $1,635,818 | $6,245,439 | $3,150,129 | $7,828,599 |

The total operating expenses for the three month period ended October 31, 2015 decreased by $4,609,621 from the three months ended October 31, 2014. The decrease is attributable to a reduction in legal fees of $295,242, an increase in consulting expense of $564,242, mainly attributable to amortization of prepaid warrant and common stock issued and by a decrease in compensation expense of $4,440,247, as we recognized stock based compensation of $249,339 in 2015 as compared to $4,023,981 in 2014.

The total operating expenses during the six months ended October 31, 2015 decreased by $4,678,470 from the six months ended October 31, 2014. The decrease is attributable to a reduction in legal fees of $431,031, an increase in consulting expense of $1,093,497, mainly attributable to the amortization of prepaid warrant and common stock issued and by a decrease in compensation expense of $4,246,095, as we recognized stock based compensation of $541,968 in 2015 as compared to $4,122,081 in 2014.

### Other income (expense), net (As Restated)

As result of the restatement of our condensed consolidated financial statements as of and for the period ended October 31, 2015 relating to the change in the accounting treatment of cashless warrants, total other income decreased by $29,746 and $492,049 for the three and six months ended October 31, 2015, respectively, due to the correction recorded to reverse the unrealized gain on the decrease in the derivative liability. As a result of the corrections, total other income decreased from $29,982 to $236 for the three months ended October 31, 2015 and from total other income of $491,558 to total other expense of $491 for the six months ended October 31, 2015.

The following tables summarize our other income (expense), net for the three and six months ended October 31, 2015 and 2014:

| Three Months Ended October 31, 2015 | 2014 | Six Months Ended October 31, 2015 | 2014 |
| ---: | ---: | ---: | ---: |
| $236 | $2,181,766 | $(491) | $2,180,102 |

Total other income, net, for the three months ended October 31, 2015 decreased by the amount of $2,181,530 from the three months ended October 31, 2014. The decrease is mainly attributable to the reduction of the gain on settlement of stock recoveries of from $2,183,331 in 2014 to $0 in 2015.

Total other expense, net, for the six months ended October 31, 2015, was $491, as compared to other income, net, of $2,180,102 for the period ended October 31, 2014. The total other income (expense), net, decrease is mainly attributable to the reduction of the gain on settlement of stock recoveries from $2,183,331 in 2014 to $0 in 2015.

### Discussion of Operating, Investing and Financing Activities

The following table presents a summary of our sources and uses of cash for the periods ended:

|  | October 31, 2015 | October 31, 2014 |
| --- | ---: | ---: |
| Net cash used in operating activities: | $(2,116,367) | (2,403,606) |
| Net cash used in investing activities: | $– | – |
| Net cash provided by (used in) financing activities: | $1,728,935 | (57,859) |
| Effect of currency rate exchange | $125 | – |
| Decrease in cash | $(387,307) | (2,461,465) |

24

***Operating Activities:***

The cash used in operating activities for the period ended October 31, 2015 is a result of our net losses: (i) offset by securities issued for services and compensation, changes to prepaid expenses, accounts payable and accrued expenses; and (ii) decreased by the reduction in license agreement liability. The cash used in operating activities for the period ended October 31, 2014 is a result of our net losses increased by stock issued, changes to prepaid expenses, accounts payable and accrued expenses.

#### Investing Activities:

There were no investing activities in the periods ended October 31, 2015 and 2014.

***Financing Activities:***

The cash provided from financing activities is mainly attributable to the proceeds from the sale of our common stock.

### Liquidity and Capital Resources

As of October 31, 2015, our cash totaled approximately $2.3 million, compared to approximately $2.7 million at April 30, 2015. Working capital was approximately $1.4 million at October 31, 2015 and approximately $800,000 at April 30, 2015. The decrease in cash is attributable to our operating expenses, net of the proceeds from the sale of our common stock.

We expect that our cash as of October 31, 2015 will be sufficient to fund our current operations and provide working capital for general corporate purposes for the next 12 months. We plan to pursue additional funding opportunities in connection with planning for and conducting our clinical trials. Among others, we intend on continuing the sale of our common stock to raise capital to fund these activities if necessary.

### Off-Balance Sheet Arrangements

Except as described below, we have no off-balance sheet arrangements that could have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.

As we reach certain “milestones” in the progression of our live cell encapsulation technology towards the development of treatments for cancer and diabetes, we will be required to make payments to SG Austria Pte. Ltd. (“SG Austria”) or Austrianova.

The future royalty and milestone payments for cancer required by the Third Addendum to the Asset Purchase Agreement we entered into with SG Austria are as follows: (i) a 2% royalty payment on all gross sales; (ii) a 10% royalty payment on all gross revenues from sublicensing; (iii) a milestone payment of $100,000 after enrollment of the first human patient in the first clinical trial for each product; (iv) a milestone payment of $300,000 after the enrollment of the first human patient in the first Phase 3 clinical trial; and (v) a milestone payment of $800,000 after obtaining a marketing authorization from a regulatory agency. Additional milestone payments of $50,000 after the enrollment of the first veterinary patient for each product and $300,000 after obtaining marketing authorization for each veterinary product are also required to be paid to SG Austria.

The future royalty and milestone payments for the treatment of diabetes required by our Licensing Agreement with Austrianova are as follows (i) a 10% royalty payment on all gross sales; (ii) a 20% percent royalty payment on gross revenues from sublicensing; (iii) a milestone payment of $100,000 after enrollment of the first human patient in the first clinical trial for each product; (iv) a milestone payment of $300,000 after the enrollment of the first human patient in the first Phase 3 clinical trial; and (v) a milestone payment of $800,000 after obtaining a marketing authorization from a regulatory agency.

The future royalty and milestone payments for the treatment of diseases and their related symptoms using constituents of the *Cannabis* plant under our Licensing Agreement with Austrianova are as follows: (i) a 10% royalty payment on all gross sales; (ii) a 20% percent royalty payment on gross revenues from sublicensing; (iii) a milestone payment of $100,000 after enrollment of the first human patient in the first clinical trial for each product; (iv) a milestone payment of $500,000 after the enrollment of the first human patient in the first Phase 3 clinical trial; and (v) a milestone payment of $800,000 after obtaining a marketing authorization from a regulatory agency.

We are also required to pay a 4.5% royalty payment on net sales for each product we develop that uses the genetically modified cells we license from Bavarian Nordic A/S and GSF-Forschungszentrum fur Umwelt u. Gesundheit GmbH.

### Critical Accounting Estimates and Policies

Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue and expenses and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends and other factors that management believes to be relevant at the time our consolidated financial statements are prepared. On a regular basis, management reviews the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with U.S. GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates and such differences could be material. Our significant accounting policies are discussed in Note 3 of Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended April 30, 2015 and Note 3 of Notes to Condensed Consolidated Financial Statements included in this Report.

We discuss our critical accounting estimates and policies in Part II, Item 7. "Management’s Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the year ended April 30, 2015. There has been no material change in our critical accounting estimates and policies since April 30, 2015.

### New Accounting Pronouncements

For a discussion of all recently adopted and recently issued but not yet adopted accounting pronouncements, see “New Accounting Pronouncements” in Note 3 of our notes to our condensed consolidated financial statements contained in this Report.

### Available Information

Our website is located at www.pharmacyte.com. The website includes a section for investor relations under which we provide notifications of news or announcements regarding our financial performance, including filings with the Commission, investor events and press and earnings releases. In addition, all PharmaCyte Biotech, Inc. filings submitted to the Commission, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, as well as other PharmaCyte Biotech, Inc. reports and statements, are available on the Commission’s web site at www.sec.gov. Such filings are also available for download free of charge on our website. The contents of the website are not intended to be incorporated by reference into this Report or any other report or document filed by us, and any reference to the websites are intended to be inactive textual references only.

## Controls and procedures

As filed, 7,663 characters.

In connection with the Original Filing, our management, including our Chief Executive Officer, President and General Counsel, as our principal executive officer and acting principal financial officer (“Principal Executive Officer” or “Principal Executive and Financial Officer”), and our Vice President of Finance (“Vice President of Finance”) evaluated the effectiveness of our “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) promulgated under the Exchange Act. Disclosure controls and procedures are designed to ensure that the information required to be disclosed in the reports that we file or submit to the Commission pursuant to the Exchange Act is recorded, processed, summarized and reported within the time period specified by the Commission’s rules and forms and is accumulated and communicated to our management, including our Principal Executive Officer, as appropriate to allow timely decisions regarding required disclosures. As reported in the Original Filing, based upon this evaluation, the Principal Executive Officer and Vice President of Finance concluded that, as of October 31, 2015, our disclosure controls and procedures were not effective due to the material weaknesses in internal control over financial reporting described in the Original Filing. In connection with the filing of this Amended Filing and the Restatements discussed above under the caption “Explanatory Note” and in Note 1A to our Restated Financial Statements, management, including our Principal Executive Officer and the Vice President of Finance, reassessed the effectiveness of our disclosure controls and procedures and concluded that, as of October 31, 2015, our disclosure controls and procedures were not effective due to the material weaknesses in internal control over financial reporting described in the Original Filing and the additional material weaknesses relating to the Restatements described below.

No control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints. Accordingly, the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. In addition, controls can be circumvented by the act of a single person, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events. Therefore, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

As of April 30, 2015, our management identified the following material weaknesses in internal control over financial reporting:

- Ineffective corporate governance;
- Ineffective communication of internal information;
- Insufficient procedures and control documentation;
- Insufficient segregation of duties; and
- Insufficient information technology controls and documentation.

As reported in the Original Filing, because of these material weaknesses, the Principal Executive Officer and the Vice President of Finance concluded that, as of April 30, 2015, our internal control over financial reporting was not effective based on the criteria outlined in *Internal Control-Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

In connection with the Restatements discussed above under the caption “Explanatory Note” and in Note 1A to our Restated Financial Statements, management, including our Principal Executive Officer and the Vice President of Finance, reassessed the effectiveness of our internal control over financial reporting as of April 30, 2015, and any changes to the Company’s internal control over financial reporting during the period ended October 31, 2015, using the COSO criteria. Based on this reassessment, management has concluded that we did not maintain effective internal control over financial reporting as of April 30, 2015, for the reasons previously identified by management, as stated above, and because of material weaknesses relating to accounting for the Consultant Agreement, certain common stock issuances and warrants and certain disclosures relating to issuances of options and common stock to directors and officers, which necessitated the Restatements. These material weaknesses resulted in a material misstatement of our liabilities, total stockholders’ equity, consolidated other income, consolidated general and administrative expenses and certain non-cash compensation expenses set forth in our audited consolidated financial statements as of and for the year ended April 30, 2015 contained in the Original Form 10-K and our condensed consolidated financial statements as of and for the periods ended July 31, 2015 and October 31, 2015 contained in the Original July Form 10-Q and the Original Filing, respectively.

As reported in the Original Filing, we have undertaken the process to review further our procedures and controls and plan to implement new procedures and controls in fiscal year 2016. Although we plan to make additional changes to our infrastructure and related processes that we believe are also reasonably likely to strengthen and materially affect our internal control over financial reporting, we have not yet made any such changes.

Prior to the remediation of these material weaknesses, there remains risk that the processes and procedures on which we currently rely will fail to be sufficiently effective. There is the possibility that this could result in material misstatement of our financial position or results of operations and require a restatement. As discussed above, because of the inherent limitations in all control systems, no evaluation of controls-even where we conclude the controls are operating effectively-can provide absolute assurance that all control issues, including instances of fraud, if any, have been detected.

The Certifications of our Principal Executive and Financial Officer required in accordance with Rule 13a-14(a) under the Exchange Act and Section 302 of the Sarbanes-Oxley Act of 2002 (“Certifications”) are attached to this Report. The disclosures set forth in this Item 4 contain information concerning: (i) the evaluation of our disclosure controls and procedures, and changes in internal control over financial reporting, referred to in paragraph 4 of the Certifications; and (ii) material weaknesses in the design or operation of our internal control over financial reporting, referred to in paragraph 5 of the Certifications. The Certifications should be read in conjunction with this Item 4 for a more complete understanding of the matters covered by the Certifications.

### Changes in Internal Control over Financial Reporting

There were no changes, other than those detailed in the preceding paragraphs (including, but not limited to, the material weaknesses which necessitated the Restatements), in our internal control over financial reporting during the most recent fiscal quarter that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 244 characters.

Reference is made to Part I, Item 1A. “Risk Factors” included in our Annual Report on Form 10-K for the year ended April 30, 2015 for information concerning risk factors. There have been no material changes in risk factors since April 30, 2015.

Filed Jan 19, 2016.
Source: SEC EDGAR, the filing index for accession 0001019687-16-004860. Last ingested by Listed: Nov 14, 2026, 20:52 ET. No prices; not investment advice.
